CD274 and neoplasm: Thus the anti-tumor immune response is inhibited by making tumor cells unrecognizable to immune cells.[2] PD-1/PD-L1 targeted inhibitors include monoclonal antibodies, polypeptide inhibitors, small molecule inhibitors, and anti-cancer vaccines.